Decoy Therapeutics Inc

DCOY Healthcare Biotechnology

In the quarter to June 2026, revenue fell 84.6%, EPS grew 94.5% and free cash flow fell 212.5%, each against the same quarter a year earlier. Insiders bought in the last twelve months.

1.17 0.06 −4.88%
Market cap
$2.9M
P/E
0.0×
Fwd P/E
−2.5×
Dividend yield
—
F-score
4/9
Altman Z
4.31
Beneish M
n/a
Dividend safety
n/a
Dec '16 Dec '17 Dec '18 Dec '19 Dec '20 Dec '21 Dec '22 Dec '23 Dec '24 Dec '25
Piotroski F-Score
— — — — 2 4 — — — —
P/E ratio
0.00 0.00 0.00 0.00 0.00 0.00 — — — —
Altman Z-Score
11,875,608.19 5,525,707.47 — (0.35) 1.58 4.31 — — — —
P/S ratio
0.00 43,395,293.79 0.00 3.93 2.50 5.92 — — — —
P/FCF ratio
0.00 0.00 0.00 0.00 0.00 0.00 — — — —
Altman Z″-Score (non-manufacturers)
13.87 (6.45) (5.91) (2.83) 7.32 19.09 — — — —
P/Operating CF
(12,432,973.90) (9,609,049.47) 0.00 (5.16) (9.54) (7.22) — — — —
Beneish M-Score
— (4.13) (5.61) — — — — — — —
P/B ratio
1,320,233.46 1,900,060.21 0.00 1.29 0.59 0.51 — — — —
EV/Sales
0.00 43,395,267.64 (3.14) 3.06 0.47 (2.74) — — — —
EV/EBITDA
0.00 0.00 3.68 0.00 0.00 0.71 — — — —
EV/FCF
(2,401,774.97) (1,987,141.01) (1.47) (0.92) (0.24) 0.89 — — — —
Current Ratio
16.06 5.91 0.81 1.42 7.06 14.29 3.40 5.02 1.98 2.13
Net Debt/EBITDA
1.54 0.97 3.68 0.46 1.37 2.28 0.38 0.46 0.42 0.85
Debt/Equity
0.00 0.00 0.00 0.00 0.02 0.00 0.00 0.00 0.00 0.00
ROE
(52.13%) (77.88%) (12.89%) (149.01%) (47.33%) (41.94%) (128.73%) (160.07%) (164.02%) (338.31%)
ROA
(49.90%) (70.12%) (8.62%) (67.64%) (39.91%) (38.83%) (113.93%) (118.12%) (116.05%) (177.82%)
ROIC
0.00% 0.00% 0.00% (75.50%) (42.25%) (84.22%) 0.00% 0.00% 0.00% 0.00%
Return on Tangible Assets
(66.79%) (118.66%) 122.29% (493.23%) (57.05%) (45.50%) (308.25%) (240.26%) (377.69%) (213.70%)
Average Days of Receivables
4.41 2.98 1.85 0.00 268.94 0.00 0.00 — — —
Earnings Yield
0.00% 0.00% (78.78%) (118.56%) (60.43%) (60.48%) — — — —
Free Cash Flow Yield
0.00% 0.00% 0.00% (85.16%) (78.66%) (51.91%) — — — —
Free Cash Flow per Share
(2.01) (1.61) 0.00 (115,801.00) (25,785.00) (9,272.91) (12,730.20) (5,585.26) (56.43) (55.71)
Book value per Share
3.65 1.69 0.00 105,809.00 55,398.00 35,202.73 6,923.07 2,298.83 18.85 60.71
Free Cash Flow
(32.61) (27.83) 4.18 (11.58) (10.31) (10.20) (19.10) (12.85) (4.53) (5.40)
EV/EBIT
0.00 0.00 3.64 0.00 0.00 0.71 — — — —
Other line items

Show all line items

Columns are period end dates